⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

Official Title: Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

Study ID: NCT03117335

Interventions

Placebos
Sulijia

Study Description

Brief Summary: The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to improve progression free survival (PFS) , disease control rate(DCR) , objective response rate(ORR) and Overall survival (OS) compared with chemotherapy alone, and evaluate the efficacy and safety of Sulijia.

Detailed Description: Recombinant endostatin injection Sulijia is a new type of recombinant protein drugs inhibiting tumor angiogenesis developed by a group of Chinese scientists and clinician. It is expressed in E. coli which Consists of 184 amino acids. It appears to be better than NP chemotherapy alone in terms of efficacy in phase I/II trials for advanced NSCLC. In this study, a randomized, double-blind, Placebo plus NP as control, multi-center phase III trial was designed to evaluate the safety and efficacy of Sulijia plus NP in the treatment of advanced NSCLC patients. PFS (progress free survival) is the primary end-point with OS (overall survival), ORR (objective response), DCR (disease control rate) and safety as the secondary end-point. A total of 560 patients have been recruited.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Bengbu medical college affiliated hospital, Bengbu, Anhui, China

The first affiliated hospital, anhui medical university, Hefei, Anhui, China

The second affiliated hospital, anhui medical university, Hefei, Anhui, China

Beijing Chest Hospital, Beijing, Beijing, China

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

Peking Union Medical College Hospital, Beijing, Beijing, China

The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China

The First Affiliated Hospital of Shantou Medical School, Shantou, Guangdong, China

Guilin medical college affiliated hospital, Guilin, Guangxi, China

The first affiliated hospital of xinxiang medical college, Xinxiang, Henan, China

The Oncology Center of Wuhan Union Hospital, Wuhan, Hubei, China

Zhongnan hospital of Wuhan University, Wuhan, Hubei, China

Changsha Central Hospital, Changsha, Hunan, China

The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

Yueyang city people's hospital, Yueyang, Hunan, China

The first People's Hospital of Changzhou, Changzhou, Jiangsu, China

Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

The People 's Liberation Army Eighth Hospital, Nanjing, Jiangsu, China

Affiliate Hospital of Nantong University, Nantong, Jiangsu, China

The first hospital affiliated to suzhou university, Suzhou, Jiangsu, China

The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

The Fourth People's Hospital of Wuxi, Wuxi, Jiangsu, China

Xuzhou medical college affiliated hospital, Xuzhou, Jiangsu, China

The First Hospital of Jilin University, Changchun, Jilin, China

People's hospital SiPingShi center, Siping, Jilin, China

Yanbian university hospital, Yanji, Jilin, China

The tumor hospital of liaoning province, Shenyang, Liaoning, China

Ningxia medical university general hospital, Yinchuan, Ningxia, China

Binzhou medical school affiliated hospital, Binzhou, Shandong, China

Jinan Central Hospital Affiliated of Shandong University, Jinan, Shandong, China

Linyi Cancer Hospital, Linyi, Shandong, China

Shanghai General Hospital, Shanghai, Shanghai, China

West China Hospital ,Sichuan University, Chengdu, Sichuan, China

The second people's hospital of yibin city, Yibin, Sichuan, China

Zhejiang cancer hospital, Hangzhou, Zhejiang, China

Contact Details

Name: Yuankai Shi, M.D.

Affiliation: Cancer Hospital Chinese Academy of Medical Science

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: